Wave life sciences announces discontinuation of suvodirsen development for duchenne muscular dystrophy

Wave life sciences announces discontinuation of suvodirsen development for duchenne muscular dystrophy.wave life sciences ltd - company is immediately discontinuing two suvodirsen trials, ole study and phase 2/3 dystance 51 trial.wave life sciences ltd - suspending further development of wve-n531 for patients with mutations amenable to exon 53 skipping.wave life sciences - expects existing cash, cash equivalents to enable wave to fund its operating, capital expenditure requirements into q3 of 2021.
WVE Ratings Summary
WVE Quant Ranking